Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 4, 2012, Pages 603-610

  Rein, Daniel T ^a   Volkmer, Anne ^a   Bauerschmitz, Gerd ^a   Beyer, Ines M ^a,b   Janni, Wolfgang ^a   Fleisch, Markus C ^a   Welter, Anne Kathrin ^a   Bauerschlag, Dirk ^c   Schöndorf, Thomas ^d   Breidenbach, Martina ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Institute for Clinical Research and Development   (Germany)

Author keywords

Chemoresistant ovarian cancer; Multidrug resistance; Murine model; Oncolytic adenovirus

Indexed keywords

ADENOVIRUS VECTOR; BEVACIZUMAB; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1E1; ONCOLYTIC ADENOVIRUS; PACLITAXEL; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MDR1 GENE; MOUSE; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CAPSID PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863102768     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1135-5     Document Type: Article

References (44)

1. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS, Gottesman MM (2004) Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66(6):1397-1405 (Pubitemid 39564766)
2. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behaviour of human epithelial ovarian cancer. Cancer Res 65(8):3025-3029. doi:10.1158/0008-5472.CAN-04-3931 (Pubitemid 40524578)
3. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A (2002) Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 62(5):1266-1270 (Pubitemid 34407775)
4. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
5. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M (2004) Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 64(12):4319-4327 (Pubitemid 38802439)
6. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72(12):9706-9713 (Pubitemid 28520834)
7. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT (2001) Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61(3):813-817 (Pubitemid 32174383)
8. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J (2006) Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-562. doi:10.1158/1078-0432.CCR- 05-1892 (Pubitemid 43166149)
9. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9(2):555-561 (Pubitemid 36182584)
10. Hoffmann D, Bangen JM, Bayer W, Wildner O (2006) Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther 13(21):1534-1544. doi:10.1038/sj.gt.3302806 (Pubitemid 44567150)
11. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9(6):1211-1218
12. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10(5):967-972. doi:10.1016/j.ymthe.2004. 08. 002 (Pubitemid 39419922)
13. Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29(45):6051-6063. doi:10.1038/onc.2010.335
14. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL (2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63(7):1490-1499 (Pubitemid 36373634)
15. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60 (5):277-300. doi:10.3322/caac.20073
16. Jessen BA, Mullins JS, De Peyster A, Stevens GJ (2003) Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol Sci 75(1):208-222 (Pubitemid 37098753)
17. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT (2002a) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8(1):275-280 (Pubitemid 34101488)
18. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A (2002b) Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 5(6):695-704 (Pubitemid 34619062)
19. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A (2003) Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptortargeted oncolytic adenovirus. Mol Ther 8(3):449-458 (Pubitemid 37167933)
20. Kanerva A, Raki M, Hemminki A (2007) Gene therapy of gynaecological diseases. Expert Opin Biol Ther 7(9):1347-1361. doi: 10.1517/14712598.7.9.1347 (Pubitemid 47485148)
21. Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26(16):2616-2618. doi: 10.1200/JCO.2008.16.2123
22. Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD, Hung MC (2003) Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res 63(19):6229-6236 (Pubitemid 37255168)
23. Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z (2004) Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 10(24):3634-3638 (Pubitemid 39619282)
24. Lu S, Wang X, Xiao L, Cai L, Zhang Y, Wang H, Wang Z (2007) Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. Cancer Biol Ther 6(3):397-404 (Pubitemid 47328308)
25. Mantwill K, Kohler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B, Holm PS (2006) Inhibition of the multidrugresistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 66(14): 7195-7202. doi:10.1158/0008-5472.CAN-05-2339 (Pubitemid 44197698)
26. Nelson AR, Davydova J, Curiel DT, Yamamoto M (2009) Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 100(11):2181-2187. doi:10.1111/j.1349-7006.2009.01289.x
27. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9(12):1769-1774 (Pubitemid 28418747)
28. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A (2005) Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12(15):1198-1205. doi:10.1038/sj.gt.3302517 (Pubitemid 41136314)
29. Raki M, Rein DT, Kanerva A, Hemminki A (2006) Gene transfer approaches for gynecological diseases. Mol Ther 14(2):154-163. doi:10.1016/j.ymthe.2006.02. 019 (Pubitemid 43942349)
30. Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A, Kanerva A (2008) Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 108(1):166-172. doi:10.1016/j.ygyno. 2007.09.013 (Pubitemid 350299441)
31. Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus-based cancer gene therapy. Future Oncol 2(1):137-143. doi:10.2217/14796694.2.1.137
32. Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A, Hess AP, Maass N, Baldus SE, Bauerschmitz G, Breidenbach M (2011) Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol Oncol 123(1): 138-146. doi:10.1016/j.ygyno.2011.06.007
33. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234. doi:10.1038/nrd1984 (Pubitemid 43336035)
34. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103(30): 11154-11159. doi:10.1073/pnas.0603672103 (Pubitemid 44156488)
35. Vanderkwaak TJ, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT (1999) An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 74(2):227-234 (Pubitemid 29377217)
36. Wrighton SA, Ring BJ, Vanden Branden M (1995) The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 23(2):199-208
37. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X (2004a) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23(12):1666-1670. doi:1000467X2004121666
38. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X (2004b) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23(12):1666-1670. doi:1000467X2004121666
39. Yadav S, van Vlerken LE, Little SR, Amiji MM (2009) Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63(4):711-722. doi:10.1007/s00280-008-0790-y
40. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT (2003) Infectivity enhanced, cyclooxygenase- 2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125(4):1203-1218 (Pubitemid 37193465)
41. You L, Yang CT, Jablons DM (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60(4):1009-1013 (Pubitemid 30129538)
42. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J, Henderson DR (2001) Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61(2):517-525 (Pubitemid 32128610)
43. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3(1):1-19 (Pubitemid 36119417)
44. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M, Widschwendter M, Bergelson JM, Marth C (2002) Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 9(16):1093-1100